News for argenx SE (ARGX)

Summary argenx SE (ARGX), a prominent global immunology company, has announced it will host a conference call and audio webcast on July 31, 2025, at 2:30 p.m. C

Baron Health Care Fund declined for the quarter but outperformed its benchmark, the Russell 3000 Health Care Index. Read more here.

PR NewswireNEW YORK, July 22, 2025 NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("arg

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (”œargenx” or the ”œCompany”) ( AR

PR NewswireNEW YORK, July 17, 2025 NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("arg

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (”œargenx” or the ”œCompany”) ( AR

PR NewswireNEW YORK, July 12, 2025 NEW YORK, July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("arg

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (”œargenx” or the ”œCompany”) ( AR

PR NewswireNEW YORK, July 7, 2025 NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argen

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (”œargenx” or the ”œCompany”) ( AR

PR NewswireNEW YORK, July 2, 2025 NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 16, Bank of America Securities analyst Tazeen Ahmad maintained a bullish stance on Argenx SE (NASDAQ:ARGX), giving it a Buy rating with an $804 price target. The analyst based the optimistic rating on the promising growth prospects […]

argenx SE (ARGX) plans to advance ARGX-119 into a registrational study following positive Phase 1b results. ARGX-119 demonstrated favorable safety and e

Summary argenx SE (ARGX), a global leader in immunology, announced on June 30, 2025, its decision to advance the clinical development of ARGX-119, a pioneering

Key Highlights: Argenx SE (ARGX) earns European Commission approval for its new treatment, Vyvgart, at a 1000 mg dose.Wall Street's average price target for ARG

Morgan Stanley's analyst, Sarita Kapila, has revised the price target for Argenx (ARGX) from EUR 715 to EUR 650. Despite the adjustment, she maintains an Overwe

Argenx (ARGX) has secured approval from the European Commission for its drug VYVGART 1000mg as a subcutaneous injection. This therapy can now be used as a stand

We came across a bullish thesis on argenx SE (ARGX) by Simvestor08 on r/valueinvesting on Reddit.. In this article, we will summarize the bulls’ thesis on ARGX.

Summary On June 3, 2025, argenx SE (ARGX), a prominent global immunology company, announced that its Chief Financial Officer, Karl Gubitz, will participate in a